Compare BioNTech SE - ADR (BNTX) vs Extra Space Storage, Inc. (EXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Extra Space Storage, Inc. — how do they compare? BioNTech SE - ADR trades at $93.04 (market cap $23.31B), while Extra Space Storage, Inc. trades at $145.62 (market cap $30.96B). The key difference: Extra Space Storage, Inc. is the larger of the two by market cap, and Extra Space Storage, Inc. pays a 4.42% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | EXR | |
|---|---|---|
Market Cap | $23.31B | $30.96B |
Sector | Health | Real Estate |
52-Week High | $119.34 | $152.85 |
52-Week Low | $83.89 | $126.67 |
Enterprise Value | $6.60B | $44.68B |
Dividend Yield | — | 4.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Extra Space Storage (EXR) trades at $146.66, down 1.93% on the day, with a bearish technical signal and neutral oscillators. The company reported strong Q2 2026 earnings, beating FFO estimates and raising full-year guidance, with revenue growth and solid same-store NOI performance. Analyst consensus is a 'Hold' with a $157.25 price target, indicating modest upside potential from current levels.
Outlook remains stable with steady revenue and earnings growth supported by acquisitions and resilient demand, though new supply and higher debt pose headwinds. Risks include competitive pressures and interest rate sensitivity, but the secure 4.3% dividend yield and strong balance sheet provide downside protection for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →
